Michael McCleod

4.5k citations
44 papers · 3.0k · 2 hit papers · h-index 17

Impact in

  • Oncology top 1%
    • Cancer Immunotherapy and Biomarkers
    • Colorectal Cancer Treatments and Studies
    • Lung Cancer Research Studies
    • Cancer Treatment and Pharmacology
    • Lung Cancer Treatments and Mutations
    • Lung Cancer Diagnosis and Treatment
    • Gastric Cancer Management and Outcomes

Papers in

    • Lung Cancer Research Studies 17
    • Cancer Immunotherapy and Biomarkers 14
    • Cancer Treatment and Pharmacology 9
    • Colorectal Cancer Treatments and Studies 7
    • Lung Cancer Treatments and Mutations 24
    • Lung Cancer Diagnosis and Treatment 9

Michael McCleod

42 papers receiving 2.9k citations

Michael McCleod's Hit Papers

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial 2019 · 1.1k citations
1.1k0+7+14Years since publication2505007501000

Peers

Michael McCleod
Comparison fields: 5 of 82
  • Oncology 2.5k
  • Pulmonary and Respiratory Medicine 1.7k
  • Hepatology 241
  • Cancer Research 276
  • Immunology 341
Replace Vera Gorbounova with:
Vera Gorbounova Russia
Davey B. Daniel United States
Jerome H. Goldschmidt United States
Alexander I. Spira United States
Daniel Waterkamp United States
Dominique Grunenwald France
G. Robinet France
Heung-Moon Chang South Korea
Atsuo Takashima Japan
Venice Archer United Kingdom
Michael McCleod relative to Vera Gorbounova Russia Vera Gorbounova's profile →
Citations per field
00.5×3.8×
Vera Gorbounova · 1×
Citations per year

Countries citing papers authored by Michael McCleod

Since Specialization
Citations

This map shows the geographic impact of Michael McCleod's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael McCleod with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael McCleod more than expected).

Fields of papers citing papers by Michael McCleod

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael McCleod. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael McCleod. The network helps show where Michael McCleod may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael McCleod, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael McCleod Line = papers co-authored together Michael McCleod links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 44 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Hit paper breakdown →
20191137
2
Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial
Hit paper breakdown →
2005709
3 2010338
4 2020118
5 2016110
6 200770
7 201755
8 201846
9 201739
10 201137
11 201735
12 201930
13 200428
14 201823
15 201118
16 201017
17 200617
18 200816
19 199516
20 201616

About Michael McCleod

Michael McCleod is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Epidemiology, Molecular Biology and Hepatology, having authored 44 papers that have together received 3.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (24 papers), Lung Cancer Research Studies (17 papers), Cancer Immunotherapy and Biomarkers (14 papers), Cancer Treatment and Pharmacology (9 papers), Lung Cancer Diagnosis and Treatment (9 papers), Colorectal Cancer Treatments and Studies (7 papers), Neuroendocrine Tumor Research Advances (7 papers) and Hepatocellular Carcinoma Treatment and Prognosis (4 papers). The work is most often cited by research in Oncology (2.5k citations), Pulmonary and Respiratory Medicine (1.7k citations), Hepatology (241 citations), Cancer Research (276 citations) and Immunology (341 citations). Michael McCleod has collaborated with scholars based in United States, Italy and Germany. Frequent co-authors include Taral Patel, Fairooz F. Kabbinavar, J. Randolph Hecht, William Novotny, R. Mass, B. Nelson, Joseph J. Schulz, John Hamm, Niels Reinmuth and Maen Hussein. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, Lung Cancer and Clinical Lung Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact